1997 Research Assistant: Department of Medical Biochemistry, Flinders University
1998-1999 Research Assistant at the Department of Cytogenetics, Women’s and Children’s Hospital. South Australia
2004-2011 Postdoctoral Researcher: Cell Growth and Differentiation Laboratory, Department of Human Immunology, Centre for Cancer Biology, Adelaide.
2012- Head, Cancer Cell Signalling Unit, Molecular Signalling Laboratory, Department of Human Immunology, Centre for Cancer Biology, Adelaide. Laboratory Head: Professor Stuart Pitson
2017- Associate faculty member of the Center of Cancer Biology
2011-2021 Affiliate Senior Lecturer, Discipline of Medicine, Faculty of Health Sciences, University of Adelaide
2016-2019 Adjunct Senior research fellow, School of Pharmacy and Medical Sciences, University of South Australia
2018- Member of the executive committee, South Australian Cancer Biobank (SACRB) 2019- Member of the Australian patient derived xenograph consortium
Excludes commercial-in-confidence projects.
Stereotactic alignment and injection system for the generation of xenografts of human brain tumours into the brains of mice for pre-clinical testing of new and existing therapeutics, Neurosurgical Research Foundation, 01/01/2018 - 31/12/2018
Research outputs for the last seven years are shown below. To see earlier years visit ORCID
Open access indicates that an output is open access.
Bassal, MA, Samaraweera, SE, Lim, K, Bernard, BA, Bailey, S, Toubia, J, Nguyen, T, Maung, KZY, Casolari, DA, Iarossi, DG, Powell, J, Pitson, S, Brown, AL, Robinson, N, Ross, DM, Gonda, TJ & D'Andrea, RJ and 10 other authors 2022, 'Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia', Nature Communications, vol. 13, article no. 2614, pp. 1-12.
Bennett, MK, Li, M, Tea, MN, Pitman, MR, Toubia, J, Wang, PP, Anderson, D, Creek, DJ, Orlowski, RZ, Gliddon, BL, Powell, JA, Wallington-Beddoe, CT & Pitson, SM 2022, 'Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition', Neoplasia, vol. 24, no. 1, pp. 1-11.
Pitman, MR, Lewis, AC, Davies, LT, Moretti, PA, Anderson, D, Creek, DJ, Powell, JA & Pitson, SM 2022, 'The sphingosine 1-phosphate receptor 2/4 antagonist JTE-013 elicits off-target effects on sphingolipid metabolism', Scientific Reports, vol. 12, no. 1, article no.454, pp. 1-12.
Open access 1 5
Neubauer, HA, Tea, MN, Zebol, JR, Gliddon, BL, Stefanidis, C, Moretti, PA, Pitman, MR, Costabile, M, Kular, J, Stringer, BW, Day, BW, Samuel, MS, Bonder, CS, Powell, JA & Pitson, SM 2019, 'Cytoplasmic dynein regulates the subcellular localization of sphingosine kinase 2 to elicit tumor-suppressive functions in glioblastoma', Oncogene, vol. 38, pp. 1151-1165.
Open access 12 12 5
Powell, JA, Pitman, MR, Zebol, JR, Moretti, PA, Neubauer, HA, Davies, LT, Lewis, AC, Dagley, LF, Webb, A I, Costabile, M & Pitson, SM 2019, 'Kelch-like protein 5-mediated ubiquitination of lysine 183 promotes proteasomal degradation of sphingosine kinase 1', Biochemical Journal, vol. 476, no. 21, pp. 3211-3226.
Open access 8 9
Wallington-Beddoe, CT, Xie, V, Tong, D, Powell, JA, Lewis, AC, Davies, L, Pitson, SM, Bradstock, KF & Bendall, LJ 2019, 'Identification of sphingosine kinase 1 as a therapeutic target in B-lineage acute lymphoblastic leukaemia', British Journal of Haematology, vol. 184, no. 3, pp. 443-447.
Open access 6 7 1
Lewis, AC, Wallington-Beddoe, CT, Powell, JA & Pitson, SM 2018, 'Targeting sphingolipid metabolism as an approach for combination therapies in haematological malignancies', Cell Death Discovery, vol. 4, no. 1, article no. 72, pp. 1-11.
Open access 38 41 1
Hein, N, Cameron, DP, Hannan, KM, Nguyen, N-Y, Powell, JA, Pitson, SM & Hannan, RD and 23 other authors 2017, 'Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population', Blood, vol. 129, pp. 2882-2895.
Open access 44 41 61
Zhu, W, Gliddon, B, Jarman, K, Moretti, P, Tin, T, Parise, L, Woodcock, J, Powell, J, Ruszkiewicz, A, Pitman, M & Pitson, S 2017, 'CIB1 contributes to oncogenic signalling by Ras via modulating the subcellular localisation of sphingosine kinase 1', Oncogene, vol. 36, no. 18, pp. 2619-2627.
Open access 24 23
Neubauer, HA, Pham, DH, Zebol, JR, Moretti, PA, Peterson, AL, Leclercq, TM, Chan, H, Powell, JA, Pitman, MR, Samuel, MS, Bonder, CS, Creek, DJ, Gliddon, BL & Pitson, SM 2016, 'An oncogenic role for sphingosine kinase 2', Oncotarget, vol. 7, no. 40, pp. 64886-64899.
Open access 41 40
Pitman, MR, Powell, JA, Coolen, C, Moretti, PA, Zebol, JR, Pham, DH, Finnie, JW, Don, AS, Ebert, LM, Bonder, CS, Gliddon, BL & Pitson, SM 2015, 'A selective ATP-competitive sphingosine kinase inhibitor demonstrates anti-cancer properties', Oncotarget, vol. 6, no. 9, pp. 7065-7083.
Open access 52 50
Wallington-Beddoe, GT, Powell, JA, Tong, D, Pitson, SM, Bradstock, KF & Bendall, LJ 2014, 'Sphingosine kinase 2 promotes acute lymphoblastic leukemia by enhancing MYC expression', Cancer Research, vol. 74, no. 10, pp. 2803-2815.
Open access 58 56
Lonic, A, Powell, JA, Kong, Y, Thomas, D, Holien, JK, Nhan, T, Parker, MW & Guthridge, MA 2013, 'Phosphorylation of serine 779 in fibroblast growth factor receptor 1 and 2 by protein kinase C epsilon regulates ras/mitogen-activated protein kinase signaling and neuronal differentiation', Journal of Biological Chemistry, vol. 288, no. 21, pp. 14874-14885.
Open access 13 13 1
External engagement & recognition
|Australian National University||AUSTRALIA|
|Harvard University||UNITED STATES|
|QIMR Berghofer Medical Research Institute||AUSTRALIA|
|St. Vincent's Institute of Medical Research||AUSTRALIA|
|Stanford University||UNITED STATES|
|University of Adelaide||AUSTRALIA|
|University of New South Wales||AUSTRALIA|
|University of North Carolina at Chapel Hill||UNITED STATES|
|University of South Australia||AUSTRALIA|
|University of Sydney||AUSTRALIA|
|University of Texas||UNITED STATES|
|Walter and Eliza Hall Institute of Medical Research||AUSTRALIA|
Supervisions from 2010 shown
|Thesis title||Student status|
|Targeting sphingosine kinase 1 to improve acute myeloid leukaemia chemotherapy.||Current|
|Targeting sphingosine kinase 1 in acute myeloid leukaemia||Completed|